Daihan PharmaceuticalLtd Future Growth

Future criteria checks 1/6

Daihan PharmaceuticalLtd is forecast to grow earnings and revenue by 7.7% and 8.6% per annum respectively. EPS is expected to grow by 6.8% per annum. Return on equity is forecast to be 11.4% in 3 years.

Key information

7.7%

Earnings growth rate

6.8%

EPS growth rate

Pharmaceuticals earnings growth	33.8%
Revenue growth rate	8.6%
Future return on equity	11.4%
Analyst coverage	Low
Last updated	09 Jan 2024

Recent future growth updates

Recent updates

Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly

Mar 02

Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Feb 09

Can You Imagine How Daihan PharmaceuticalLtd's (KOSDAQ:023910) Shareholders Feel About The 34% Share Price Increase?

Jan 19

What Kind Of Shareholders Hold The Majority In Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Shares?

Dec 18

Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?

Nov 27

Earnings and Revenue Growth Forecasts

KOSDAQ:A023910 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	232,600	33,200	31,900	37,950	2
12/31/2024	212,850	30,800	29,800	36,200	2
12/31/2023	195,911	28,426	17,580	38,860	N/A
9/30/2023	194,528	26,211	24,146	39,159	N/A
6/30/2023	192,259	26,521	23,159	35,516	N/A
3/31/2023	189,043	26,089	24,761	33,110	N/A
12/31/2022	184,268	24,961	20,378	28,999	N/A
9/30/2022	181,122	26,197	20,739	29,322	N/A
6/30/2022	177,126	25,029	21,550	29,953	N/A
3/31/2022	173,726	23,690	25,409	36,413	N/A
12/31/2021	171,463	22,670	28,767	40,617	N/A
9/30/2021	166,619	16,680	26,576	36,612	N/A
6/30/2021	165,495	16,166	23,433	32,278	N/A
3/31/2021	162,372	15,568	23,107	29,355	N/A
12/31/2020	166,080	17,381	28,267	33,627	N/A
9/30/2020	170,116	26,246	20,905	32,312	N/A
6/30/2020	170,011	26,438	28,291	40,193	N/A
3/31/2020	172,492	28,702	22,201	38,203	N/A
12/31/2019	168,762	28,167	17,959	35,264	N/A
9/30/2019	165,178	27,408	26,351	39,995	N/A
6/30/2019	161,926	27,618	24,255	39,859	N/A
3/31/2019	158,298	28,256	-1,723	43,297	N/A
12/31/2018	158,720	28,518	-1,748	44,944	N/A
9/30/2018	153,402	26,631	-11,210	44,796	N/A
6/30/2018	152,130	27,449	-16,533	38,153	N/A
3/31/2018	149,083	26,148	7,703	30,615	N/A
12/31/2017	144,439	24,832	-592	20,455	N/A
9/30/2017	145,319	23,702	N/A	17,452	N/A
6/30/2017	140,743	21,183	N/A	19,191	N/A
3/31/2017	140,077	18,881	N/A	22,031	N/A
12/31/2016	139,437	17,657	N/A	27,924	N/A
9/30/2016	134,843	16,853	N/A	23,294	N/A
6/30/2016	131,994	15,774	N/A	21,432	N/A
3/31/2016	128,845	15,285	N/A	20,744	N/A
12/31/2015	124,276	13,776	N/A	17,975	N/A
9/30/2015	121,296	12,275	N/A	15,661	N/A
6/30/2015	118,698	11,126	N/A	14,635	N/A
3/31/2015	114,739	9,817	N/A	10,230	N/A
12/31/2014	111,709	10,420	N/A	9,483	N/A
9/30/2014	109,610	10,000	N/A	13,633	N/A
6/30/2014	107,834	7,924	N/A	10,318	N/A
3/31/2014	107,229	8,305	N/A	13,680	N/A
12/31/2013	106,803	7,771	N/A	12,686	N/A
9/30/2013	105,028	7,655	N/A	9,757	N/A
6/30/2013	102,700	9,145	N/A	14,531	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A023910's forecast earnings growth (7.7% per year) is above the savings rate (2.5%).

Earnings vs Market: A023910's earnings (7.7% per year) are forecast to grow slower than the KR market (29% per year).

High Growth Earnings: A023910's earnings are forecast to grow, but not significantly.

Revenue vs Market: A023910's revenue (8.6% per year) is forecast to grow slower than the KR market (9.1% per year).

High Growth Revenue: A023910's revenue (8.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A023910's Return on Equity is forecast to be low in 3 years time (11.4%).

Daihan PharmaceuticalLtd Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target decreased to ₩40,000

Price target decreased to ₩40,000

Recent updates

Upcoming dividend of ₩650 per share at 2.3% yield

Upcoming dividend of ₩400 per share

Price target decreased to ₩40,000

No independent directors

Price target decreased to ₩40,000

No independent directors

Inaugural dividend of ₩400 per share

Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly

New 90-day high: ₩35,350

Daihan Pharmaceutical Co.,Ltd., Annual General Meeting, Mar 25, 2021

Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Can You Imagine How Daihan PharmaceuticalLtd's (KOSDAQ:023910) Shareholders Feel About The 34% Share Price Increase?

New 90-day high: ₩34,050

What Kind Of Shareholders Hold The Majority In Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Shares?

Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?

New 90-day low: ₩29,100

New 90-day high - ₩33,700

New 90-day high - ₩32,150

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies